Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hydromorphone + naltrexone is a combination of two pharmaceutical agents. Hydromorphone is a potent opioid analgesic used for the management of moderate-to-severe acute and chronic pain, acting primarily as an agonist at the mu-opioid receptor to produce analgesia[4]. Naltrexone is an opioid antagonist that competitively binds to mu-, kappa-, and delta-opioid receptors, with highest affinity for the mu receptor, thereby blocking or reversing the effects of opioids such as euphoria and respiratory depression[5][8]. When combined in a single formulation, naltrexone serves as an abuse-deterrent component; if the product is tampered with (e.g., crushed), naltrexone becomes bioavailable and counteracts hydromorphone’s opioid effects, reducing potential for misuse or abuse[6]. Such combinations have been developed to provide effective pain relief while minimizing risk of opioid abuse.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydromorphone + naltrexone.